Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Biogen Q1 2024 Adj EPS $3.67 Beats $3.44 Estimate, Sales $2.291B Miss $2.311B Estimate

Author: Benzinga Newsdesk | April 24, 2024 06:49am
Biogen (NASDAQ:BIIB) reported quarterly earnings of $3.67 per share which beat the analyst consensus estimate of $3.44 by 6.69 percent. This is a 7.94 percent increase over earnings of $3.40 per share from the same period last year. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.311 billion by 0.87 percent. This is a 7.00 percent decrease over sales of $2.463 billion the same period last year.

Posted In: BIIB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist